We were thankful to be in Silver Spring, Maryland at the U.S Food and Drug Administration (FDA) headquarters for the Patient-Focused Drug Development (PFDD) meeting on September 11, 2017. The FDA gathered feedback from more than 200 people living with alopecia areata, caregivers and parents, members of the research community and other interested parties, with another 200 participating via webinar online. Participants shared their experiences and insights about living with the disease. Later, the FDA published a “The Voice of the Patient” report with all feedback received. The FDA selected alopecia areata as one of 24 diseases to explore with patients through its Patient-Focused Drug Development (PFDD) program.